MA55088A - Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire - Google Patents

Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire

Info

Publication number
MA55088A
MA55088A MA055088A MA55088A MA55088A MA 55088 A MA55088 A MA 55088A MA 055088 A MA055088 A MA 055088A MA 55088 A MA55088 A MA 55088A MA 55088 A MA55088 A MA 55088A
Authority
MA
Morocco
Prior art keywords
cancer therapy
immune checkpoint
checkpoint inhibitor
benzene compound
alkynyl benzene
Prior art date
Application number
MA055088A
Other languages
English (en)
Inventor
Hiroshi Hirai
Kazuaki Matsuoka
Kazuhiko Yonekura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA55088A publication Critical patent/MA55088A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055088A 2019-02-28 2020-02-28 Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire MA55088A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JP2019112619 2019-06-18

Publications (1)

Publication Number Publication Date
MA55088A true MA55088A (fr) 2022-01-05

Family

ID=72239799

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055088A MA55088A (fr) 2019-02-28 2020-02-28 Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire
MA055091A MA55091A (fr) 2019-02-28 2020-02-28 Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055091A MA55091A (fr) 2019-02-28 2020-02-28 Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab

Country Status (8)

Country Link
US (2) US20220184082A1 (fr)
EP (2) EP3932425A4 (fr)
JP (7) JPWO2020175704A1 (fr)
KR (4) KR20260085356A (fr)
AU (4) AU2020229714B2 (fr)
MA (2) MA55088A (fr)
TW (2) TW202045182A (fr)
WO (2) WO2020175697A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US20220348662A1 (en) * 2019-09-26 2022-11-03 Janssen Pharmaceutica Nv Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2025046272A1 (fr) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Méthodes de traitement du cancer à l'aide de futibatinib et de pembrolizumab

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
AU2013210403B2 (en) * 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
JP6084292B2 (ja) * 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EA201890161A1 (ru) * 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫
KR20250007056A (ko) * 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물

Also Published As

Publication number Publication date
MA55091A (fr) 2022-01-05
KR20210131387A (ko) 2021-11-02
EP3932427A1 (fr) 2022-01-05
AU2020228514A1 (en) 2021-10-07
AU2025203861A1 (en) 2025-06-19
JP2026116557A (ja) 2026-07-09
JP2024152860A (ja) 2024-10-25
AU2020228514B2 (en) 2025-02-27
JPWO2020175704A1 (fr) 2020-09-03
KR20260085356A (ko) 2026-06-09
JP2025075059A (ja) 2025-05-14
US20220184082A1 (en) 2022-06-16
JP2023112136A (ja) 2023-08-10
KR20260085357A (ko) 2026-06-09
AU2025203865A1 (en) 2025-06-19
US20220125793A1 (en) 2022-04-28
KR20210130774A (ko) 2021-11-01
JPWO2020175697A1 (fr) 2020-09-03
TW202045182A (zh) 2020-12-16
TW202039507A (zh) 2020-11-01
AU2020229714B2 (en) 2025-02-27
WO2020175704A1 (fr) 2020-09-03
EP3932425A1 (fr) 2022-01-05
WO2020175697A1 (fr) 2020-09-03
AU2020229714A1 (en) 2021-10-07
JP2023096156A (ja) 2023-07-06
EP3932425A4 (fr) 2022-12-07
EP3932427A4 (fr) 2022-12-07

Similar Documents

Publication Publication Date Title
EP3919500A4 (fr) Composé et dispositif électroluminescent organique le comprenant
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
EP3881162A4 (fr) Dispositif électronique comprenant un corps coulissant
EP3885350A4 (fr) Nouveau composé de bore et dispositif électroluminescent organique le comprenant
EP3960744A4 (fr) Composé aromatique polycyclique condensé par un cycloalcane
EP3466926A4 (fr) Composé pour élément électronique organique, élément électronique organique l'utilisant et dispositif électronique associé
EP3932425A4 (fr) Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire
CO2017006813A2 (es) Composiciones inhibidoras de corrosion para tratamientos acidificantes
EP3730490A4 (fr) Composé pour dispositif électronique organique, dispositif électronique organique l'utilisant et dispositif électronique associé
DK3685809T3 (da) Stimuleringsanordning til en mands penis
EP3901158A4 (fr) Composé polycyclique et élément électroluminescent organique le comprenant
PL3942445T3 (pl) Delegowane zarządzanie uprawnieniami przy użyciu karty zbliżeniowej
DK3752490T3 (da) Herbicide 3-azaspiro[5.5]undecan-8,10-dionforbindelser
CL2023001863S1 (es) Autoinyector portátil .
EP3686186A4 (fr) Composé, composition de revêtement le comprenant, et diode électroluminescente organique
DK3811931T3 (da) Kombinationslægemiddel indeholdende en liposomsammensætning, der indkapsler et lægemiddel, og en immun-checkpoint-hæmmer
KR102668958B9 (ko) 브루톤 티로신 키나아제 억제제인 치환된 1-아미노-1h-이미다졸-5-카르복사미드
EP3974433A4 (fr) Élément électroluminescent organique, composé et appareil électronique
EP3915982A4 (fr) Composé et dispositif électroluminescent organique comprenant celui-ci
EP4046992A4 (fr) Composé organique et dispositif électroluminescent organique le comprenant
MA54243A (fr) Composé de 1,3,4-oxadiazolone et médicament
EP3854224A4 (fr) Inhibiteur de point de contrôle immunitaire
EP3874641A4 (fr) Détermination d'un livre de codes de rétroaction
EP3998321A4 (fr) Composé électroluminescent organique et dispositif électroluminescent organique
EP4035528A4 (fr) Composé 7-oxa-3,4-diazabicyclo[4.1.0]hepta-4-ène-2-one et herbicide